NASDAQ:KMPH

Zevra Therapeutics (KMPH) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$4.48
$6.27
52-Week Range
N/A
Volume
64,100 shs
Average Volume
189,500 shs
Market Capitalization
$200.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
KMPH stock logo

About Zevra Therapeutics Stock (NASDAQ:KMPH)

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

KMPH Stock News Headlines

The only accurate crypto trading system I know …
Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.
The only accurate crypto trading system I know …
Juan Villaverde is no ordinary crypto trader. His proprietary timing algorithm has led him to rack up a series of gains of 477%, 333% and 153% on Bitcoin … It pointed the way to Cardano, at just 4 cents …Helping investors make 29 times their money.
See More Headlines
Receive KMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/30/2022
Today
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KMPH
Employees
22
Year Founded
N/A

Profitability

Net Income
$-8,560,000.00
Net Margins
-328.56%
Pretax Margin
-335.26%

Debt

Sales & Book Value

Annual Sales
$10.72 million
Book Value
$3.63 per share

Miscellaneous

Free Float
34,125,000
Market Cap
$200.47 million
Optionable
Optionable
Beta
2.16
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

KMPH Stock Analysis - Frequently Asked Questions

How were Zevra Therapeutics' earnings last quarter?

Zevra Therapeutics, Inc. (NASDAQ:KMPH) released its earnings results on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, hitting analysts' consensus estimates of ($0.08). Zevra Therapeutics had a negative net margin of 328.56% and a negative trailing twelve-month return on equity of 16.12%.

What other stocks do shareholders of Zevra Therapeutics own?
When did Zevra Therapeutics IPO?

Zevra Therapeutics (KMPH) raised $60 million in an initial public offering (IPO) on Thursday, April 16th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

This page (NASDAQ:KMPH) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners